 |
||
 |
|
|
 |
||
|
|
|
 |
||||
|
|
|
|
|
 |
 |
|||
|
|
|
|
|
 |
 |
 |
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Risk Assessment
Exposure Asssment
October 14, 2005
MEETING SUMMARY
NATIONAL TOXICOLOGY PROGRAM
CENTER FOR THE EVALUATION OF RISKS
TO HUMAN REPRODUCTION
EXPERT PANEL RE-EVALUATION OF DEHP
OCTOBER 10–12, 2005
(continued)
Next Steps
The final expert panel report from this re-evaluation of DEHP will be posted on the CERHR web site (http://cerhr.niehs.nih.gov) and available in printed text from the CERHR in November, 2005. The CERHR will solicit public comments on this report through an announcement in the Federal Register. Following this comment period, the CERHR will prepare the NTP-CERHR monograph on DEHP, consisting of an NTP brief, expert panel report, and all public comments on that report. The monograph will be available to the public on the CERHR web site and in hardcopy from CERHR. The monograph will be sent to appropriate federal health and regulatory agencies.
Background
The NTP established the CERHR in 1998 as a public resource for providing scientifically based, uniform assessments of the potential for adverse effects on reproduction and/or development caused by man-made or naturally occurring chemicals or chemical mixtures to which humans are exposed. The CERHR convenes independent panels of scientific experts to conduct its evaluations. Expert panel meetings are open to the public and the public is invited to nominate scientists to serve on CERHR expert panels. Following completion of the evaluation of a chemical, the NTP prepares an NTP-CERHR monograph that contains its opinion on the potential for the chemical to be a reproductive or developmental hazard, the expert panel report, and public comments received on the final expert panel report. NTP-CERHR monographs on other chemicals evaluated by CERHR include six phthalates, methanol, 1-bromopropane, 2-bromopropane, ethylene glycol, propylene glycol, fluoxetine (ProzacŪ), acrylamide, amphetamines, methylphenidate, and styrene and are available on the CERHR web site or in hardcopy from CERHR.
Questions about the expert panel review or CERHR can be directed to Dr. Michael Shelby, CERHR Director at 919-541-3455 or shelby@niehs.nih.gov
DEHP2
